

Dasatinib

Recent Results in Cancer Research

212, 29-68

DOI: 10.1007/978-3-319-91439-8_2

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1862.	2.2	86
2	A novel anti-melanoma SRC-family kinase inhibitor. <i>Oncotarget</i> , 2019, 10, 2237-2251.	0.8	13
3	Chylothorax: complication attributed to dasatinib use. <i>BMJ Case Reports</i> , 2019, 12, e231653.	0.2	11
4	Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 672-678.	1.0	7
5	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
6	Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e042814.	0.8	9
8	The Role of Eph Receptors and Ephrins in Corneal Physiology and Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4567.	1.8	1
9	Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers. <i>Cancers</i> , 2021, 13, 1930.	1.7	24
10	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19
11	Ovalbumin Antigen-Specific Activation of Human T Cell Receptor Closely Resembles Soluble Antibody Stimulation as Revealed by BOOST Phosphotyrosine Proteomics. <i>Journal of Proteome Research</i> , 2021, 20, 3330-3344.	1.8	4
12	Eph Receptors and Ephrins in Retinal Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6207.	1.8	6
13	Co-receptor signaling in the pathogenesis of neuroHIV. <i>Retrovirology</i> , 2021, 18, 24.	0.9	9
14	Anti-aging: senolytics or gerostatics (unconventional view). <i>Oncotarget</i> , 2021, 12, 1821-1835.	0.8	18
15	A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 728155.	1.3	9
16	Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein. <i>Journal of Molecular Modeling</i> , 2021, 27, 309.	0.8	4
17	Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance. <i>Drug Delivery</i> , 2021, 28, 670-679.	2.5	15
18	Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 1539-1550.	2.5	3
19	β2-Adrenoceptor Activation Stimulates IL-6 Production via PKA, ERK1/2, Src, and Beta-Arrestin2 Signaling Pathways in Human Bronchial Epithelia. <i>Lung</i> , 2021, 199, 619-627.	1.4	5

#	ARTICLE	IF	CITATIONS
20	Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS. <i>Current Drug Metabolism</i> , 2020, 21, 1022-1030.	0.7	3
21	A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities. <i>Blood Research</i> , 2021, 56, 229-242.	0.5	19
22	The Implications of Bone Marrow Adipose Tissue on Inflammaging. <i>Frontiers in Endocrinology</i> , 2022, 13, 853765.	1.5	19
23	Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics. <i>Frontiers in Pharmacology</i> , 2021, 12, 797881.	1.6	11
24	Molecular Classification and Therapeutic Targets in Ependymoma. <i>Cancers</i> , 2021, 13, 6218.	1.7	22
25	Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties. <i>Molecules</i> , 2022, 27, 5436.	1.7	38
26	Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	1
27	Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia. <i>Journal of Personalized Medicine</i> , 2022, 12, 1607.	1.1	2
28	The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
29	Structural and Functional Changes in Aging Kidneys. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15435.	1.8	12
30	Combined PARP inhibitors and small molecular inhibitors in solid tumor treatment (Review). <i>International Journal of Oncology</i> , 2023, 62, .	1.4	3
31	Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age. <i>Aging Cell</i> , 2023, 22, .	3.0	34
32	Synthetic Approaches for Pharmacologically Active Decorated Six-Membered Diazines. , 0, , .		0
33	The Chemoprevention of Hereditary Diffuse Gastric Cancer. , 2023, , 321-341.		0
34	New Concepts in the Manipulation of the Aging Process. <i>Current Stem Cell Research and Therapy</i> , 2024, 19, 178-184.	0.6	1
35	A disposable electrochemical sensor based on single-walled carbon nanotubes for the determination of anticancer drug dasatinib. <i>Monatshefte für Chemie</i> , 0, , .	0.9	0
36	Imatinib Analogs in Chronic Myeloid Leukemia: a Systematic Qualitative Review. <i>Current Pharmacology Reports</i> , 0, , .	1.5	0
40	Quercetin and dasatinib, two powerful senolytics in age-related cardiovascular disease. <i>Biogerontology</i> , 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
42	Resistance of prostate cancer to kinase inhibitors. , 2024, , 179-211.		0
44	Molecular Implications of BCR-ABL1 in Hematological Malignancies. , 2023, , .		0